Description: Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Home Page: www.herontx.com
4242 Campus Point Court
San Diego,
CA
92121
United States
Phone:
858 251 4400
Officers
| Name | Title |
|---|---|
| Mr. Craig Alexander Collard | CEO & Director |
| Ms. Ira Duarte | Executive VP & CFO |
| Dr. William P. Forbes Pharm. D., Pharm.D. | Executive VP & Chief Development Officer |
| Mr. Ryan Craig | Vice President of Marketing |
| Mr. Sean T. Ristine | Senior Vice President of Human Resources |
| Mr. Robert Sullivan | Senior Vice President of Oncology Care Franchise & Commercial Operations |
| Mr. Brett Fleshman | Chief Business Officer |
| Jeff Cohn | Executive Director, Assistant General Counsel & Assistant Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.087 |
| Price-to-Sales TTM: | 1.8068 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 126 |